-
1Academic Journal
Συγγραφείς: M. M. Tlish, T. G. Kuznetsova, M. E. Shavilova, F. A. Psavok, М. М. Тлиш, Т. Г. Кузнецова, М. Е. Шавилова, Ф. А. Псавок
Πηγή: Meditsinskiy sovet = Medical Council; № 2 (2025); 91-96 ; Медицинский Совет; № 2 (2025); 91-96 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: наружная терапия, topical glucocorticosteroids, betamethasone dipropionate, external therapy, топические глюкокортикостероиды, бетаметазона дипропионат
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8953/7782; Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther. 2021;11(3):769–797. https://doi.org/10.1007/s13555-021-00521-z.; Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/234_2.; Sriramoju S, Dunde S, Eggadi V, Koppolu MS, Seshagiri SBB. Evaluation of depression and quality of life in patients with psoriasis. Int J Dermatol Venereol. 2022;5(1):27–31. https://doi.org/10.1097/JD9.0000000000000180.; Vičić M, Kaštelan M, Brajac I, Sotošek V, Massari LP. Current concepts of psoriasis immunopathogenesis. Int J Mol Sci. 2021;22(21):11574. https://doi.org/10.3390/ijms222111574.; Suzuki T, Ito T, Gilhar A, Tokura Y, Reich K, Paus R. The hair follicle-psoriasis axis: shared regulatory mechanisms and therapeutic targets. Exp Dermatol. 2022;31(3):266–279. https://doi.org/10.1111/exd.14462.; Polak-Witka K, Rudnicka L, Blume-Peytavi U, Vogt A. The role of the microbiome in scalp hair follicle biology and disease. Exp Dermatol. 2020;29(3):286–294. https://doi.org/10.1111/exd.13935.; Shah RR, Larrondo J, Dawson T, Mcmichael A. Scalp microbiome: a guide to better understanding scalp diseases and treatments. Arch Dermatol Res. 2024;316(8):495. https://doi.org/10.1007/s00403-024-03235-2.; Butacu AI, Toma C, Negulet IE, Manole I, Banica AN, Please A et al. Updates on psoriasis in special areas. J Clin Med. 2024;13(24):7549. https://doi.org/10.3390/jcm13247549.; Huang S, Bai Y. Knowledge mapping and research hotspots of comorbidities in psoriasis: a bibliometric analysis from 2004 to 2022. Medicina. 2023;59(2):393. https://doi.org/10.3390/medicina59020393.; Тлиш ММ, Кузнецова ТГ, Шавилова МЕ, Сычева НЛ, Псавок ФА. Коморбидность у больных хроническими вирусными инфекциями: особенности течения дерматологической патологии. Лечащий врач. 2018;(11):49–53. Режим доступа: https://www.lvrach.ru/2018/11/15437131.; Тлиш ММ, Кузнецова ТГ, Наатыж ЖЮ, Сычева НЛ, Шавилова МЕ, Гаврилова НВ и др. Совершенствование методов диагностики и лечения хронических дерматозов аутоиммунного генеза. Краснодар: Кубанский государственный медицинский университет; 2022. 236 с.; Svedbom A, Mallbris L, Larsson P, Nikamo P, Wolk K, Kjellman P et al. Longterm outcomes and prognosis in new-onset psoriasis. JAMA Dermatol. 2021;157(6):684–690. https://doi.org/10.1001/jamadermatol.2021.0734.; Тлиш ММ, Шавилова МЕ. Контактный дерматит: этиопатогенетические аспекты формирования клинической картины и рациональный выбор наружной терапии. Медицинский совет. 2023;(14):37–42. https://doi.org/10.21518/ms2023-263.; Тлиш ММ, Шавилова МЕ, Сычева НЛ, Псавок ФА. Топические глюкокортикостероиды: от высокой клинической эффективности к проблеме бесконтрольного применения (обзор клинических случаев). Медицинский совет. 2023;(6):186–192. https://doi.org/10.21518/ms2023-043.; Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26(3):36–46. https://doi.org/10.1111/j.1468-3083.2012.04522.x.; Белоусова ТА, Каиль МВ. Терапевтические возможности наружных глюкокортикостероидов в современной клинической практике. Медицинский совет. 2020;(12):36–45. https://doi.org/10.21518/2079-701X2020-12-36-45.
-
2Academic Journal
Συγγραφείς: Ju. S. Kovaleva, M. V. Orobei, N. K. Zyablitskaya, R. E. Goltsov, Ю. С. Ковалева, М. В. Оробей, Н. К. Зяблицкая, Р. Е. Гольцов
Πηγή: Meditsinskiy sovet = Medical Council; № 14 (2024); 152-162 ; Медицинский Совет; № 14 (2024); 152-162 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: топические глюкокортикостероиды, hair dye, permanent makeup, eyelash extensions, manicure, piercing, topical glucocorticosteroids, краска для волос, перманентный макияж, наращивание ресниц, маникюр, пирсинг
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8544/7503; Власов МВ, Хабибрахманова ЕВ. Повышение эффективности бизнеса в сфере бьюти-индустрии (индустрии красоты). Вестник Академии знаний. 2022;53(6):410–415. Режим доступа: https://academiyadt.ru/wp-content/uploads/vaz/vaz-53-6.pdf.; González-Muñoz P, Conde-Salazar L, Vañó-Galván S. Allergic contact dermatitis caused by cosmetic products. Actas Dermosifiliogr. 2014;105(9):822–832. https://doi.org/10.1016/j.ad.2013.12.018.; Owen JL, Vakharia PP, Silverberg JI. The Role and Diagnosis of Allergic Contact Dermatitis in Patients with Atopic Dermatitis. Am J Clin Dermatol. 2018;19(3):293–302. https://doi.org/10.1007/s40257-017-0340-7.; Novak-Bilić G, Vučić M, Japundžić I, Meštrović-Štefekov J, Stanić-Duktaj S, Lugović-Mihić L. Irritant and allergic contact dermatitis – skin lesion characteristics. Acta Clin Croat. 2018;57(4):713–720. https://doi.org/10.20471/acc.2018.57.04.13.; Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. https://doi.org/10.1016/j.jaad.2005.01.010.; Jamil W, Svensson Å, Josefson A, Lindberg M, Von Kobyletzki L. Incidence Rate of Hand Eczema in Different Occupations: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2022;102:adv00681. https://doi.org/10.2340/actadv.v102.360.; Havmose MS, Kezic S, Uter W, Symanzik C, Hallmann S, Strahwald J et al. Prevalence and incidence of hand eczema in hairdressers-A systematic review and meta-analysis of the published literature from 2000–2021. Contact Dermatitis. 2022;86(4):254–265. https://doi.org/10.1111/cod.14048.; Uter W, Gefeller O, Schwanitz HJ. Early onset irritant skin damage in apprentice hair dressers. Hautarzt. 1995;46(11):771–778. https://doi.org/10.1007/s001050050337.; Uter W, Bensefa-Colas L, Frosch P, Giménez-Arnau A, John SM, Lepoittevin JP et al. Patch testing with hair cosmetic series in Europe: a critical review and recommendation. Contact Dermatitis. 2015;73(2):69–81. https://doi.org/10.1111/cod.12424.; Søsted H, Hesse U, Menné T, Andersen KE, Johansen JD. Contact dermatitis to hair dyes in a Danish adult population: an interview-based study. Br J Dermatol. 2005;153(1):132–135. https://doi.org/10.1111/j.1365-2133.2005.06588.x.; Diepgen TL, Naldi L, Bruze M, Cazzaniga S, Schuttelaar ML, Elsner P et al. Prevalence of Contact Allergy to p-Phenylenediamine in the European General Population. J Invest Dermatol. 2016;136(2):409–415. https://doi.org/10.1016/j.jid.2015.10.064.; Warshaw EM, Peterson MY, Atwater AR, DeKoven JG, Pratt MD, Taylor JS et al. Patch Testing to Paraphenylenediamine: The North American Contact Dermatitis Group Experience (1994–2018). Dermatitis. 2023;34(6):536–546. https://doi.org/10.1089/derm.2023.0140.; Uter W, Strahwald J, Hallmann S, Johansen JD, Havmose MS, Kezic S et al. Systematic review on skin adverse effects of important hazardous hair cosmetic ingredients with a focus on hairdressers. Contact Dermatitis. 2023;88(2):93–108. https://doi.org/10.1111/cod.14236.; Schubert S, Lessmann H, Schnuch A, Uter W, Geier J. Factors associated with p-phenylenediamine sensitization: data from the Information Network of Departments of Dermatology, 2008–2013. Contact Dermatitis. 2018;78(3):199–207. https://doi.org/10.1111/cod.12920.; Uter W, Hallmann S, Gefeller O, Brans R, Symanzik C, Oppel E et al. Contact allergy to ingredients of hair cosmetics in female hairdressers and female consumers-An update based on IVDK data 2013–2020. Contact Dermatitis. 2023;89(3):161–170. https://doi.org/10.1111/cod.14363.; Teixeira M, de Wachter L, Ronsyn E, Goossens A. Contact allergy to para-phenylenediamine in a permanent eyelash dye. Contact Dermatitis. 2006;55(2):92–94. https://doi.org/10.1111/j.0105-1873.2006.00883.x.; Ali L, Foulds JS, Abdul Ghaffar S. Severe eyelid allergic contact dermatitis secondary to eyelash tint: two case reports. Contact Dermatitis. 2017;77(1):59–60. https://doi.org/10.1111/cod.12749.; Kaiserman I. Severe allergic blepharoconjunctivitis induced by a dye for eyelashes and eyebrows. Ocul Immunol Inflamm. 2003;11(2):149–151. https://doi.org/10.1076/ocii.11.2.149.15921.; Awan MA, Lockington D, Ramaesh K. Severe allergic blepharoconjunctivitis after eyelash colouring. Eye (Lond). 2010;24(1):200–201. https://doi.org/10.1038/eye.2009.50.; Bacharewicz-Szczerbicka J, Reduta T, Pawłoś A, Flisiak I. Paraphenylenediamine and related chemicals as allergens responsible for allergic contact dermatitis. Arch Med Sci. 2019;17(3):714–723. https://doi.org/10.5114/aoms.2019.86709.; Gargano EM, Blömeke B, Gaspari AA, Goebel C. The 2-Methoxymethyl Modification of p -Phenylenediamine Reduces the Sensitization Risk for Hairdressers to Hair Dyes-An Occupational Hand Exposure-Based Risk Assessment. Dermatitis. 2022;33(4):293–301. https://doi.org/10.1097/DER.0000000000000915.; Pang S, Fiume MZ. Final report on the safety assessment of Ammonium, Potassium, and Sodium Persulfate. Int J Toxicol. 2001;20(3):7–21. https://doi.org/10.1080/10915810152630710.; Warshaw EM, Ruggiero JL, DeKoven JG, Pratt MD, Silverberg JI, Maibach HI et al. Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018. J Am Acad Dermatol. 2022;87(5):1014–1023. https://doi.org/10.1016/j.jaad.2021.08.005.; Warshaw EM, Ruggiero JL, DeKoven JG, Maibach HI, Atwater AR, Taylor JS et al. Contact Dermatitis Associated With Hair Care Products: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001–2016. Dermatitis. 2022;33(1):91–102. https://doi.org/10.1097/DER.0000000000000760.; Özkaya E, Elinç Aslan MS. Occupational allergic contact dermatitis: A 24-year, retrospective cohort study from Turkey. Contact Dermatitis. 2021;85(5):503–513. https://doi.org/10.1111/cod.13938.; Gregoriou S, Mastraftsi S, Hatzidimitriou E, Tsimpidakis A, Nicolaidou E, Stratigos A et al. Occupational and non-occupational allergic contact dermatitis to hair dyes in Greece. A 10-year retrospective study. Contact Dermatitis. 2020;83(4):277–285. https://doi.org/10.1111/cod.13598.; Angres GG. Eye-liner implants: a new cosmetic procedure. Plast Reconstr Surg. 1984;73(5):833–836. https://doi.org/10.1097/00006534-198405000-00022.; Wilkes TD. The complications of dermal tattooing. Ophthalmic Plast Reconstr Surg. 1986;2(1):1–6. https://doi.org/10.1097/00002341-198601040-00001.; Simons KB, Payne CM, Heyde RR. Blepharopigmentation: histopathologic observations and X-ray microanalysis. Ophthalmic Plast Reconstr Surg. 1988;4(1):57–62.; Goldberg H, Berger Y, Ben Bassat I, Barequet I. Inadvertent corneal pigmentation following cosmetic blepharopigmentation. Am J Ophthalmol Case Rep. 2018;12:52–54. https://doi.org/10.1016/j.ajoc.2018.09.002.; Wenzel SM, Welzel J, Hafner C, Landthaler M, Bäumler W. Permanent makeup colorants may cause severe skin reactions. Contact Dermatitis. 2010;63(4):223–227. https://doi.org/10.1111/j.1600-0536.2010.01799.x.; Calzado L, Gamo R, Pinedo F, Vicente FJ, Naz E, Gómez-de la Fuente E et al. Granulomatous dermatitis due to blepharopigmentation. J Eur Acad Dermatol Venereol. 2008;22(2):235–236. https://doi.org/10.1111/j.1468-3083.2007.02291.x.; Bee CR, Steele EA, White KP, Wilson DJ. Tattoo granuloma of the eyelid mimicking carcinoma. Ophthalmic Plast Reconstr Surg. 2014;30(1):e15–17. https://doi.org/10.1097/IOP.0b013e31828ad7b7.; Greywal T, Cohen PR. Cosmetic tattoo pigment reaction. Dermatol Online J. 2016;22(7):13030/qt3rc114rg. Available at: https://pubmed.ncbi.nlm.nih.gov/27617722.; Masud M, Moshirfar M, Shah TJ, Gomez AT, Avila MR, Ronquillo YC. Eyelid Cosmetic Enhancements and Their Associated Ocular Adverse Effects. Med Hypothesis Discov Innov Ophthalmol. 2019;8(2):96–103. Available at: https://pubmed.ncbi.nlm.nih.gov/31263720.; Forbat E, Al-Niaimi F. Patterns of Reactions to Red Pigment Tattoo and Treatment Methods. Dermatol Ther (Heidelb). 2016;6(1):13–23. https://doi.org/10.1007/s13555-016-0104-y.; Serup J, Hutton Carlsen K. Patch test study of 90 patients with tattoo reactions: negative outcome of allergy patch test to baseline batteries and culprit inks suggests allergen(s) are generated in the skin through haptenization. Contact Dermatitis. 2014;71(5):255–263. https://doi.org/10.1111/cod.12271.; Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol. 2005;141(7):869–872. https://doi.org/10.1001/archderm.141.7.869.; Ebrahimiadib N, Adelpour F, Ghahari M, Mehrpour M. Intermediate Uveitis Associated with Tattooing of Eyebrows as a Manifestation of Systemic Sarcoidosis: Report of Two Cases. Ocul Immunol Inflamm. 2021;29(5):902–905. https://doi.org/10.1080/09273948.2019.1699581.; Martín JM, Revert A, Monteagudo C, Villalón G, Godoy R, Jordá E. Granulomatous reactions to permanent cosmetic tattoos successfully treated with topical steroids and allopurinol. J Cosmet Dermatol. 2007;6(4):229–231. https://doi.org/10.1111/j.1473-2165.2007.00338.x.; Wang WM, Zhu CY, Jin HZ, Zeng YP. Systemic sarcoidosis revealed by sarcoidal granulomas on eyebrow tattoos. Eur J Dermatol. 2018;28(4):561–562. https://doi.org/10.1684/ejd.2018.3347.; Huisman S, van der Bent SAS, Wolkerstorfer A, Rustemeyer T. Granulomatous tattoo reactions in permanent makeup of the eyebrows. J Cosmet Dermatol. 2019;18(1):212–214. https://doi.org/10.1111/jocd.12540.; Islam PS, Chang C, Selmi C, Generali E, Huntley A, Teuber SS et al. Medical Complications of Tattoos: A Comprehensive Review. Clin Rev Allergy Immunol. 2016;50(2):273–286. https://doi.org/10.1007/s12016-016-8532-0.; Abah ER, Oladigbolu KK, Rafindadi AL, Audu O. Eyelash extension use among female students in a Tertiary Institution in Nigeria: A study of kaduna polytechnic, Kaduna. Niger J Clin Pract. 2017;20(12):1639–1643. https://doi.org/10.4103/njcp.njcp_124_17.; Amano Y, Sugimoto Y, Sugita M. Ocular disorders due to eyelash extensions. Cornea. 2012;31(2):121–125. https://doi.org/10.1097/ICO.0b013e31821eea10.; Nagendran ST, Ali MJ, Dogru M, Malhotra R. Complications and adverse effects of periocular aesthetic treatments. Surv Ophthalmol. 2022;67(3):741–757. https://doi.org/10.1016/j.survophthal.2021.04.009.; Kim YJ, Chung JK. Bilateral Eyelid Contact Dermatitis and Toxic Conjunctivitis due to Acrylate-Containing Glue. Ann Dermatol. 2014;26(4):543–544. https://doi.org/10.5021/ad.2014.26.4.543.; Shanmugam S, Wilkinson M. Allergic contact dermatitis caused by a cyanoacrylate-containing false eyelash glue. Contact Dermatitis. 2012;67(5):309–310. https://doi.org/10.1111/cod.12000.; Xiong M, Shaik JA, Hylwa S. Formaldehyde Release From Eyelash Glues: Analysis Using the Chromotropic Acid Method. Dermatitis. 2022;33(6):442–446. https://doi.org/10.1097/DER.0000000000000910.; Moshirfar M, Masud M, Shah TJ, Avila MR, Hoopes PCSr. Chemical conjunctivitis and diffuse lamellar keratitis after removal of eyelash extensions. Am J Ophthalmol Case Rep. 2018;12:21–23. https://doi.org/10.1016/j.ajoc.2018.07.007.; Gardeen S, Hylwa S. A review of acrylates: Super glue, nail adhesives, and diabetic pump adhesives increasing sensitization risk in women and children. Int J Womens Dermatol. 2020;6:263–267. https://doi.org/10.1016/j.ijwd.2020.04.007.; Opalińska S, Opalińska M, Rudnicka L, Czuwara J. Contact eczema induced by hybrid manicure. The role of acrylates as a causative factor. Adv Dermatol Allergol. 2022;39(4):768–774. https://doi.org/10.5114/ada.2021.109684.; Militello M, Hu S, Laughter M, Dunnick C. American contact dermatitis society allergens of the year 2000 to 2020. Dermatol Clin. 2020;38(3):309–320. https://doi.org/10.1016/j.det.2020.02.011.; Gonçalo M, Pinho A, Agner T, Andersen KE, Bruze M, Diepgen T et al. Allergic contact dermatitis caused by nail acrylates in Europe. An EECDRG study. Contact Dermatitis. 2018;78(4):254–260. https://doi.org/10.1111/cod.12942.; Kucharczyk M, Słowik-Rylska M, Cyran-Stemplewska S, Gieroń M, Nowak-Starz G, Kręcisz B. Acrylates as a significant cause of allergic contact dermatitis: new sources of exposure. Postepy Dermatol Alergol. 2021;38(4):555–560. https://doi.org/10.5114/ada.2020.95848.; Havmose M, Thyssen JP, Zachariae C, Johansen JD. Artificial Nails and Longlasting Nail Polish in Danish Hairdressers: Self-use, Occupational Exposure and Related Eczema. Acta Derm Venereol. 2022;102:adv00818. https://doi.org/10.2340/actadv.v102.4524.; Kieć-Świerczyńska M, Świerczyńska-Machura D, Chomiczewska-Skóra D, Kręcisz B, Walusiak-Skorupa J. Screening survey of ocular, nasal, respiratory and skin symptoms in manicurists in Poland. Int J Occup Med Environ Health. 2017;30(6):887–896. https://doi.org/10.13075/ijomeh.1896.00961.; Riera-Martí N, Expósito-Serrano V, Sin M, Gamissans M, López-Llunell C, Ribera M. Vulvar allergic contact dermatitis to multiple acrylates: a case report. Int J Womens Dermatol. 2023;9(1):e077. https://doi.org/10.1097/JW9.0000000000000077.; Тамразова ОБ, Селезнев CП. Аллергический контактный дерматит на никель. Медицинский совет. 2022;16(3):121–129. https://doi.org/10.21518/2079-701X-2022-16-3-121-129.; Karagounis TK, Cohen DE. Occupational Hand Dermatitis. Curr Allergy Asthma Rep. 2023;23(4):201–212. https://doi.org/10.1007/s11882-023-01070-5.; Roque Quintana B, Falcón Hernández A, Sagrera Guedes A, Borrego L. Contact Dermatitis to Allergens in the Spanish Standard Series: Patch Test Findings in the South of Gran Canaria. Actas Dermosifiliogr. 2022;113(6):555–562. https://doi.org/10.1016/j.ad.2022.02.027.; Ahlström MG, Menné T, Thyssen JP, Johansen JD. Nickel allergy in a Danish population 25 years after the first nickel regulation. Contact Dermatitis. 2017;76(6):325–332. https://doi.org/10.1111/cod.12782.; Ahlström MG, Thyssen JP, Wennervaldt M, Menné T, Johansen JD. Nickel allergy and allergic contact dermatitis: A clinical review of immunology, epidemiology, exposure, and treatment. Contact Dermatitis. 2019;81(4):227–241. https://doi.org/10.1111/cod.13327.; Goldenberg A, Mousdicas N, Silverberg N, Powell D, Pelletier JL, Silverberg JI et al. Pediatric Contact Dermatitis Registry Inaugural Case Data. Dermatitis. 2016;27(5):293–302. https://doi.org/10.1097/DER.0000000000000214.; Warshaw EM, Aschenbeck KA, DeKoven JG, Maibach HI, Taylor JS, Sasseville D et al. Piercing and Metal Sensitivity: Extended Analysis of the North American Contact Dermatitis Group Data, 2007–2014. Dermatitis. 2017;28(6):333–341. https://doi.org/10.1097/DER.0000000000000324.; Schuttelaar MLA, Ofenloch RF, Bruze M, Cazzaniga S, Elsner P, Gonçalo M et al. Prevalence of contact allergy to metals in the European general population with a focus on nickel and piercings: The EDEN Fragrance Study. Contact Dermatitis. 2018;79(1):1–9. https://doi.org/10.1111/cod.12983.; Markel K, Silverberg N, Pelletier JL, Watsky KL, Jacob SE. Art of prevention: A piercing article about nickel. Int J Womens Dermatol. 2019;6(3):203–205. https://doi.org/10.1016/j.ijwd.2019.03.001.; Zemelka-Wiacek M. Metal Allergy: State-of-the-Art Mechanisms, Biomarkers, Hypersensitivity to Implants. J Clin Med. 2022;11(23):6971. https://doi.org/10.3390/jcm11236971.; Borghini R, De Amicis N, Bella A, Greco N, Donato G, Picarelli A. Beneficial Effects of a Low-Nickel Diet on Relapsing IBS-Like and Extraintestinal Symptoms of Celiac Patients during a Proper Gluten-Free Diet: Nickel Allergic Contact Mucositis in Suspected Non-Responsive Celiac Disease. Nutrients. 2020;12(8):2277. https://doi.org/10.3390/nu12082277.; Picarelli A, Greco N, Sciuttini F, Marini C, Meacci A. High consumption of Nickel-containing foods and IBS-like disorders: late events in a gluten-free diet. Ecotoxicol Environ Saf. 2021;222:112492. https://doi.org/10.1016/j.ecoenv.2021.112492.; Fors R, Stenberg B, Stenlund H, Persson M. Nickel allergy in relation to piercing and orthodontic appliances--a population study. Contact Dermatitis. 2012;67(6):342–350. https://doi.org/10.1111/j.1600-0536.2012.02097.x.
-
3Academic Journal
Συγγραφείς: Lyubimova E.V., Savlevich E.L., Zurochka A.V., Mitrofanova Е.S.
Συνεισφορές: 1
Πηγή: Russian Journal of Infection and Immunity; Vol 14, No 6 (2024); 1070-1078 ; Инфекция и иммунитет; Vol 14, No 6 (2024); 1070-1078 ; 2313-7398 ; 2220-7619
Θεματικοί όροι: chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, COVID-19, SARS-CoV-2, angiotensin-converting enzyme (ACE)-2, local glucocorticosteroid, systemic glucocorticosteroid, frequency of hospitalization, biological therapy, post-COVID syndrome, хронический риносинусит, полипозный риносинусит, ангиотензинпревращающий фермент (ACE)-2, системные глюкокортикостероиды, топические глюкокортикостероиды, частота госпитализации, биологическая терапия, постковидный синдром
Περιγραφή αρχείου: application/pdf
Relation: https://iimmun.ru/iimm/article/view/16667/2120; https://iimmun.ru/iimm/article/view/16667/2160; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129011; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129012; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129013; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129014; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129015; https://iimmun.ru/iimm/article/view/16667
-
4Academic Journal
Πηγή: Рецепт. :121-130
Θεματικοί όροι: 0301 basic medicine, эмоллиенты, 03 medical and health sciences, 0302 clinical medicine, топические глюкокортикостероиды, atopic dermatitis, probiotics, topical glucocorticosteroids, пробиотики, атопический дерматит, emollients, 3. Good health
-
5Academic Journal
Συγγραφείς: Kataeva, A. D., Omelkova, D. M., Kupriyanova, I. N., Naumova, V. V., Bozrov, R. M., Катаева, А. Д., Омелькова, Д. М., Куприянова, И. Н., Наумова, В. В., Бозров, Р. М.
Πηγή: Сборник статей
Θεματικοί όροι: EOSINOPHILIC ESOPHAGITIS, ESOPHAGEAL EOSINOPHILIA, PROTON PUMP INHIBITORS, TOPICAL GLUCOCORTICOSTEROIDS, ЭОЗИНОФИЛЬНЫЙ ЭЗОФАГИТ, ЭОЗИНОФИЛИЯ ПИЩЕВОДА, ИНГИБИТОРЫ ПРОТОННОЙ ПОМПЫ, ТОПИЧЕСКИЕ ГЛЮКОКОРТИКОСТЕРОИДЫ
Περιγραφή αρχείου: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/13467
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/13467
-
6Academic Journal
Συγγραφείς: M. M. Tlish, Z. Yu. Naatyzh, T. G. Kuznetsova, М. М. Тлиш, Ж. Ю. Наатыж, Т. Г. Кузнецова
Πηγή: Meditsinskiy sovet = Medical Council; № 3 (2022); 95-100 ; Медицинский Совет; № 3 (2022); 95-100 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: аллергодерматозы, ceramides, clinical efficacy, topical therapy, topical glucocorticosteroids, allergic dermatosis, керамиды, топическая терапия, топические глюкокортикостероиды
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6746/6088; Ковалева Ю.С., Ведлер А.А., Кожевникова П.Е. Роль керамидов в сохранении эпидермального барьера. Клиническая дерматология и венерология. 2019;18(4):513–518. https://doi.org/10.17116/klinderma201918041513.; Kato A., Fukai K., Oiso N., Murakami T., Ishii M. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. Br J Dermatol. 2003;148(4): 665–669. https://doi.org/10.1046/j.1365-2133.2003.05243.x.; Волошин Р.Н., Тлиш М.М., Наатыж Ж.Ю., Кузнецова Т.Г. Клиническая эффективность препарата «Айсида»-бальзам для укрепления жирных волос при жирной себорее. Медицинский вестник Юга России. 2014;(2):122–124. Режим доступа: https://www.medicalherald.ru/jour/article/view/204/205.; Матушевская Е.В., Свирщевская Е.В. Технологии микронизации лекарственных препаратов: новые возможности топических глюкокортикостероидов в дерматологии. Клиническая дерматология и венерология. 2017;16(1):43–48. http://doi.org/10.17116/klinderma201716143-48.; Соколовский Е.В. Кожные и венерические болезни. СПб.: Фолиант; 2008. 520 c. Режим доступа: https://docplayer.com/29153680-Sokolovskiy-e-vkozhnye-i-venericheskie-bolezni-uchebnoe-posobie-dlya-studentov-medicinskih-vuzov-spb-foliant-s.html.; Зайцева С.В., Застрожина А.К., Муртазаева О.А. Наружная терапия атопического дерматита у детей. Медицинский совет. 2017;(19):149–152. http://doi.org/10.21518/2079-701X-2017-19-149-152.; Хардикова С.А., Дмитрук В.С. Современные аспекты топической терапии атопического дерматита у детей. Клиническая дерматология и венерология. 2019;18(1):56–62. https://doi.org/10.17116/klinderma20191801156.
-
7Academic Journal
Συγγραφείς: A. V. Kostetskaia, E. I. Kasikhina, M. N. Ostretsova, A. L. Savastenko, N. N. Potekaev, А. В. Костецкая, Е. И. Касихина, М. Н. Острецова, А. Л. Савастенко, Н. Н. Потекаев
Πηγή: Meditsinskiy sovet = Medical Council; № 3 (2022); 47-54 ; Медицинский Совет; № 3 (2022); 47-54 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: комбинированные препараты, combined topical glucocorticosteroids, gentamicin sulfate, dexpanthenol, mometasone furoate, econazole nitrate cream, кожные заболевания, дерматиты, топические глюкокортикостероиды
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6734/6077; Christoffers W.A., Coenraads P.-J., Svensson А., Diepgen T.L., Dickinson-Blok J.L., Xia J., Williams H.C. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4(4):CD004055. https://doi.org/10.1002/14651858.CD004055.pub2.; Appelen D., Romijn-Bucarciuc D., Stenveld H., Visch M.B. Hand eczema in COVID-19 outbreak: whether or not to wear gloves? Ned Tijdschr Geneeskd. 2020;164:D5252. Available at: https://www.ntvg.nl/artikelen/handeczeem-tijden-van-corona.; Thyssen J.P., Johansen J.D., Linneberg A., Menné T. The epidemiology of hand eczema in the general population – prevalence and main findings. Contact Dermatitis. 2010;62(2):75–87. https://doi.org/10.1111/j.1600-0536.2009.01669.x.; Diepgen T.L., Andersen K.E., Chosidow O., Coenraads P.J., Elsner P., English J. et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1–e22. https://doi.org/10.1111/ddg.12510_1.; Diepgen Т.L., Pfarr Е., Zimmermann Т. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92(3):251–255. https://doi.org/10.2340/00015555-1256.; Cazzaniga S., Apfelbacher C., Diepgen T., Ofenloch R.F., Weisshaar E., Molinet S. et al. Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. Br J Dermatol. 2018;178(1):229–237. https://doi.org/10.1111/bjd.15660.; Elston D.M., Ahmed D.D.F., Watsky K.L., Schwarzenberger K. Hand dermatitis. J Am Acad Dermatol. 2002;47(2):291–299. https://doi.org/10.1067/mjd.2002.122757.; Scalone L., Cortesi P.A., Mantovani L.G., Belisari A., Ayala F., Fortina A.B. et al. Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: Results from Italy. Br J Dermatol. 2015;172(1):187–195. https://doi.org/10.1111/bjd.13220.; Apfelbacher C., Molin S., Weisshaar E., Bauer A., Elsner P., Mahler V. et al. Characteristics and provision of care in patients with chronic hand eczema: Updated data from the CARPE registry. Acta Derm Venereol. 2014;94(2):163–167. https://doi.org/10.2340/00015555-1632.; Salvador S.J.F., Mendaza F.H., Garcés M.H., Palacios-Martínez D., Sánchez Camacho R., Sanzet R.S. et al. Guidelines for the Diagnosis, Treatment, and Prevention of Hand Eczema. Actas Dermosifiliogr (Engl Ed). 2020;111(1):26–40. https://doi.org/10.1016/j.ad.2019.04.005.; Agner T., Aalto-Korte K., Andersen K.E., Foti C., Gimenéz-Arnau A., Goncalo M. et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29(12):2417–2422. https://doi.org/10.1111/jdv.13308.; Thyssen J.P., Schuttelaar M.L.A., Alfonso J.H., Andersen K.E., Angelova-Fischer I., Arents B.M.W. et al. Guidelines for diagnosis, prevention and treatment of hand eczema. Contact Dermatitis. 2021. https://doi.org/10.1111/cod.14035.; Coenraads P.-J. Hand eczema. N Engl J Med. 2012;367(19):1829–1837. https://doi.org/10.1056/NEJMcp1104084.; Sarmiento P.M.C., Azanza J.J.C. Dyshidrotic Eczema: A Common Cause of Palmar Dermatitis. Cureus. 2020;12(10):e10839. https://doi.org/10.7759/cureus.10839.; Wollina U. Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2010;11(5):305–314. https://doi.org/10.2165/11533250-000000000-00000.; Minocha Y.C., Dogra A., Sood V.K. Contact sensitivity in palmer hyperkeratotic dermatitis. Indian J Dermatol Venerol Leprol. 1993;59:60–63. Available at: https://ijdvl.com/contact-sensitivity-in-palmar-hyperkeratotic-dermatitis/.; Nielsen J. The occurrence and course of skin symptoms on the hands among female cleaners. Contact Dermatitis. 1996;34(4):284–291. https://doi.org/10.1111/j.1600-0536.1996.tb02201.x.; Reinholz M., Kendziora B., Frey S., Oppel E.M., Ruëff F., Clanner-Engelshofen B.M. et al. Increased prevalence of irritant hand eczema in health care workers in a dermatological clinic due to increased hygiene measures during the SARS-CoV-2 pandemic. Eur J Dermatol. 2021;31(3):392–395. https://doi.org/10.1684/ejd.2021.4046.; Singh M., Pawar M., Bothra A., Choudhary N. Overzealous hand hygiene during the COVID 19 pandemic causing an increased incidence of hand eczema among general population. J Am Acad Dermatol. 2020;83(1):e37–e41. https://doi.org/10.1016/j.jaad.2020.04.047.; Berents T.L., Saunes M., Schopf T., Vindenes H.K. Atopisk eksem. Tidsskr Nor Laegeforen. 2018;138(13). https://doi.org/10.4045/tidsskr.18.0071.; Leung A.K.C., Lam J.M., Leong K.F., Leung A.A.M., Wong A.H.C., Hon K.L. Nummular Eczema: An Updated Review. Recent Pat Inflamm Allergy Drug Discov. 2020;14(2):146–155. https://doi.org/10.2174/1872213X14666200810152246.; Crane M.M., Webb D.J., Watson E., Cunliffe T., English J. Hand eczema and steroid-refractory chronic hand eczema in general practice: prevalence and initial treatment. Br J Dermatol. 2017;176(4):955–964. https://doi.org/10.1111/bjd.14974.; Berthold E., Weisshaar E. Treatment of hand eczema. Hautarzt. 2019;70(10):790–796. https://doi.org/10.1007/s00105-019-04475-4.; Dubin С., Del Duca Е., Guttman-Yassky Е. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319–1332. https://doi.org/10.2147/TCRM.S292504.; De León F.J., Berbegal L., Silvestre J.F. Management of Chronic Hand Eczema. Actas Dermosifiliogr. 2015;106(7):533–544. https://doi.org/10.1016/j.ad.2015.04.005.; Kao J.S., Fluhr J.W., Man M.-Q., Fowler A.J., Hachem J.-P., Crumrine D. et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol. 2003;120(3):456–464. https://doi.org/10.1046/j.1523-1747.2003.12053.x.; Guenther L., Lynde C., Poulin Y. Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders. J Cutan Med Surg. 2019;23(4_suppl): 27S–34S. https://doi.org/10.1177/1203475419857668.; Song M., Lee H.-J., Lee W.-K. Kim H.-S., Ko H.-C., Kim M.-B., Kim B.-S. Acitretin as a Therapeutic Option for Chronic Hand Eczema. Annals of dermatology. 2017;29(3): 385–387. https://doi.org/10.5021/ad.2017.29.3.385.; Gritiyarangsan P., Sukhum A., Tresukosol P., Kullavanijaya P. Topical PUVA therapy for chronic hand eczema. J Dermatol. 1998;25(5):299–301. https://doi.org/10.1111/j.1346-8138.1998.tb02401.x.; Sezer E., Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed. 2007;23(1):10–14. https://doi.org/10.1111/j.1600-0781.2007.00258.x.; Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 1999;41(3 Pt 2):S22–S4. https://doi.org/10.1016/s0190-9622(99)70362-2.; Haslund P., Bangsgaard N., Jarløv J.O., Skov L., Skov R., Agner T. Staphylococcus aureus and hand eczema severity. Br J Dermatol. 2009;161(4):772–777. https://doi.org/10.1111/j.1365-2133.2009.09353.x.; Mernelius S., Carlsson Е., Henricson J., Löfgren S., Lindgren P.-E., Ehricht R. et al. Staphylococcus aureus colonization related to severity of hand eczema. Eur J Clin Microbiol Infect Dis. 2016;35(8):1355–1361. https://doi.org/10.1007/s10096-016-2672-2.; Nørreslet L.B., Lilje B., Ingham A.C., Edslev S.M., Clausen M.-L., Plum F. et al. Skin Microbiome in Patients with Hand Eczema and Healthy Controls: A Three-week Prospective Study. Acta Derm Venereol. 2022;102:adv00633. https://doi.org/10.2340/actadv.v101.845.; Byrd A.L., Belkaid Y., Segre J.A. The human skin microbiome. Nat Rev Microbiol. 2018;16(3):143–155. https://doi.org/10.1038/nrmicro.2017.157.; Bay L., Ring H.C. Human skin microbiota in health and disease: The cutaneous communities’ interplay in equilibrium and dysbiosis: The cutaneous communities’ interplay in equilibrium and dysbiosis. APMIS. 2021. https://doi.org/10.1111/apm.13201.; Никонова И.В., Орлов Е.В., Коннов П.Е. Состояние биоценоза кожи при микробной экземе. Практическая медицина. 2011;2(49):80–83. Режим доступа: https://cyberleninka.ru/article/n/sostoyanie-biotsenoza-kozhi-primikrobnoy-ekzeme/viewer.; Петровский Ф.И., Коростовцев Д.С. Активированный цинка пиритион при атопическом дерматите у детей. Механизм действия, клиническая эффективность. Педиатрическая фармакология. 2009;6(2):67–71. Режим доступа: https://www.pedpharma.ru/jour/issue/viewIssue/53/38.; Moriwaki M., Iwamoto K., Niitsu Y., Matsushima A., Yanase Y., Hisatsune J. et al. Staphylococcus aureus from atopic dermatitis skin accumulates in the lysosomes of keratinocytes with induction of IL-1α secretion via TLR9. Allergy. 2019;74(3):560–571. https://doi.org/10.1111/all.13622.; Кубанов А.А., Хардикова С.А., Заславский Д.В., Новиков Ю.А., Радул Е.В., Правдина О.В. и др. Экзема: клинические рекомендации. М.; 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/246_2.; Abou-Zeid A.A., Shehata Y.M. Gentamicins. Zentralbl Bakteriol Parasitenkd Infektionskr Hyg. 1977;132(2):97–108. https://doi.org/10.1016/s0044-4057(77)80051-8.; Das М.С., Biswas А., Chowdhury M., Saha J. Screening Antimicrobial Susceptibility of Gentamicin, Vancomycin, Azithromycin, Chloramphenicol and Cefotaxime Against Selected Gram Positive and Gram Negative Bacteria. Int J Pharma Res Health Sci. 2014;2(4):324–331. Avaliable at: http://www.pharmahealthsciences.net/pdfs/VOLUME-2-ISSUE-42014/8_1485.pdf.; Naimi H.M, Rasekh H., Noori A.Z, Bahaduri M.A. Determination of antimicrobial susceptibility patterns in Staphylococcus aureus strains recovered from patients at two main health facilities in Kabul, Afghanistan. BMC Infect Dis. 2017;17(1):737. https://doi.org/10.1186/s12879-017-2844-4.; Simonetti N., Spignoli G., D’Auria F.D., Strippoli V. Antimicrobial contact activity of econazole sulfosalicylate. J Chemother. 1991;3(2):101–107. https://doi.org/10.1080/1120009x.1991.11739074.; Gorski J., Proksch E., Baron J.M., Schmid D., Zhang L. Dexpanthenol in Wound Healing after Medical and Cosmetic Interventions (Postprocedure Wound Healing). Pharmaceuticals (Basel). 2020;13(7):138. https://doi.org/10.3390/ph13070138.; Wiederholt T., Heise R., Skazik C., Marquardt Y., Joussen S., Erdmann K. et al. Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009;18(11):969–978. https://doi.org/10.1111/j.1600-0625.2009.00884.x.; Тлиш М.М., Кузнецова Т.Г., Наатыж Ж.Ю., Псавок Ф.А. Микробная экзема: возможности коррекции на современном этапе. Вестник дерматологии и венерологии. 2018;94(4):60–67. https://doi.org/10.25208/0042-4609-2018-94-4-60-67.; Кунгуров Н.В., Кохан М.М., Кениксфест Ю.В., Кащеева Я.В., Летаева О.В., Куклин И.А., Стукова Е.И. Инновационное комбинированное наружное средство в терапии осложненных дерматозов: опыт использования. Лечащий врач. 2019;(5):38–49. Режим доступа: https://www.lvrach.ru/2019/05/15437294.; Яковлев А.Б., Круглова Л.С. Дисгидроз и дисгидрозиформные дерматозы: особенности клиники, диагностики и лечения. Клиническаядерматология и венерология. 2018;17(4):72–78. https://doi.org/10.17116/klinderma20181704172.; Круглова Л.С., Федоров Д.В., Стенько А.Г., Грязева Н.В., Яковлев А.Б. Актуальные рекомендации по применению многокомпонентного препарата в дерматологии. Медицинский алфавит. 2019;2(26):67–72. https://doi.org/10.33667/2078-5631-2019-2-26(401)-67-72.; Шперлинг Н.В., Шперлинг И.А., Юркевич Ю.В. Эффективность наружной терапии дисгидротической экземы комбинированным препаратом. Клиническая дерматология и венерология. 2020;19(2):200–204. https://doi.org/10.17116/klinderma202019021200.
-
8Academic Journal
Συγγραφείς: Rinat K. Raupov, Mikhail M. Kostik, Р. К. Раупов, М. М. Костик
Συνεισφορές: The article is supported by RFBR grant № 18-515-57001., Работа поддержана грантом РФФИ № 18-515-57001.
Πηγή: Current Pediatrics; Том 19, № 3 (2020); 228-234 ; Вопросы современной педиатрии; Том 19, № 3 (2020); 228-234 ; 1682-5535 ; 1682-5527
Θεματικοί όροι: генно-инженерные биологические препараты, morphea, linear morphea, topical glucocorticosteroids, tacrolimus, methotrexat, mycophenolate mofetil, genetically engineered biologic drugs, морфея, линейная склеродермия, топические глюкокортикостероиды, такролимус, метотрексат, микофенолата мофетил
Περιγραφή αρχείου: application/pdf
Relation: https://vsp.spr-journal.ru/jour/article/view/2397/942; Кубанова А. А., Кубанов А. А., Мелехина Л. Е., Богданова Е. В. Анализ состояния заболеваемости болезнями кожи и подкожной клетчатки в Российской Федерации за период 2003– 2016 гг. //Вестник дерматологии и венерологии. — 2017. — № 6. — С. 22–33. doi:10.25208/0042-4609-2017-93-6-22-33.; Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–613. doi:10.1097/01.bor.0000245727.40630.c3.; Zulian F, Culpo R, Sperotto F, et al. (2019). Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019;78(8):1019–1024. doi:10.1136/annrheumdis-2018-214697.; Kienast A, Foeldvari I. High Prevalence of Extracutaneous Manifestations and Comorbidities in 108 Patients with Juvenile Localized Scleroderma. Ann Rheum Dis. 2015;74(Suppl 2):612. doi:10.1136/annrheumdis-2015-eular.1675.; Condie D, Grabell D, Jacobe H. Morphea in Adults and Children Cohort VI: A cross-sectional comparison of outcomes between adults with pediatric-onset and adult-onset morphea. Arthritis Rheumatol. 2014;66(12):3496–3504. doi:10.1002/art.38853.; Knobler R, Moinzadeh P, Hunzelmann N, et al. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol. 2017;31(9):1401–1424. doi:10.1111/jdv.14458.; Torok KS, Li SC, Jacobe HM, et al. Immunopathogenesis of Pediatric Localized Scleroderma. Front Immunol. 2019;10:908. doi:10.3389/fimmu.2019.00908.; Constantin T, Foeldvari I, Pain CE, et al. Development of minimum standards of care for juvenile localized scleroderma. Eur J Pediatr. 2018;177(7):961–977. doi:10.1007/s00431-018-3144-8.; Li SC, Feldman BM, Higgins GC, et al. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol. 2010:37:175–181. doi:10.3899/jrheum.090708.; Prinz JC, Kutasi Z, Weisenseel P, et al. «Borrelia-associated early-onset mophea»: a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. J Am Acad Dermatol. 2009;60(2):248–255. doi:10.1016/j.jaad.2008.09.023.; Локализованная склеродермия: клинические рекомендации /Российское общество дерматовенерологов и косметологов. — 2016.; Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol. 2000;142(4):636–644. doi:10.1046/j.1365-2133.2000.03407.x.; Fan W, Leonardi CL, Penneys NS. Absence of Borrelia burgdorferi in patients with localized scleroderma (morphea). J Am Acad Dermatol. 1995;33(4):682–684. doi:10.1016/0190-9622(95)91311-4.; Kreuter A, Krieg T, Worm M, et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges. 2016;14(2):199–216. doi:10.1111/ddg.12724.; National Center for Biotechnology Information. PubChem Database. Calcipotriol, CID=5288783. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Calcipotriol. Accessed on April 25, 2020).; Cunningham BB, Landells ID, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39(2 Pt 1):211–215. doi:10.1016/s0190-9622(98)70077-5.; Kreuter A, Gambichler T, Avermaete A, et al. Combined treatment with calcipotriol ointment and lowdose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol. 2001;18(3):241–245. doi:10.1046/j.1525-1470.2001.018003241.x.; Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 65: 925–941, 2011; Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol. 2007;157(3):615–618. doi:10.1111/j.1365-2133.2007.07971.x; Ahluwalia A. Topical glucocorticoids and the skin — mechanisms of action: an update. Mediators Inflamm. 1998;7(3):183–193. doi:10.1080/09629359891126.; Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol. 2002;138(1):99–105. doi:10.1001/archderm.138.1.99.; Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol. 2011;64:231–242; quiz 243–244. doi:10.1016/j.jaad.2010.05.046.; Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–241. doi:10.1067/mjd.2002.120942.; Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(9):181–187. doi:10.2165/00128071-200910030-00004.; Stefanaki C, Stefanaki K, Kontochristopoulos G, et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol. 2008;35:712–718. doi:10.1111/j.1346-8138.2008.00552.x.; Mancuso G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol. 2003;13(6):590–592.; Vidal D. Topical Imiquimod: Mechanism of Action and Clinical Applications. Mini Rev Med Chem. 2006;6(5), 499–503. doi:10.2174/138955706776876131.; Dytoc M, Ting PT, Man J, et al. First case series on the use of imiquimod for morphoea. Br J Dermatol. 2005;153(4):815–820. doi:10.1111/j.1365-2133.2005.06776.x.; Pope E, Doria AS, Theriault M, et al. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology. 2011;223(4):363–369. doi:10.1159/000335560.; Keyal U, Bhatta AK, Wang XL. UVA1 a promising approach for scleroderma. Am J Transl Res. 2017;9(9):4280–4287.; Kreuter A, Hyun J, Stucker M, et al. A randomized controlled study of lowdose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440–447. doi:10.1016/j.jaad.2005.11.1063.; Asano Y, Fujimoto M, Ishikawa O. Diagnostic criteria, severity classification and guidelines of localized scleroderma. J Dermatol. 2018;45(7):755–780. doi:10.1111/1346-8138.14161.; Lythgoe H, Almeida B, Bennett J, et al. Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management. Pediatr Rheumatol Online J. 2018;16(1):80. doi:10.1186/s12969-018-0295-0.; Saxton-Daniels S, Jacobe HT An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Dermatol. 2010;146(9):1044–1045. doi:10.1001/archdermatol.2010.239.; Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151–1156. doi:10.1016/j.jaad.2012.03.036.; Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol. 2012;39(2):286–94. doi:10.3899/jrheum.110210.; Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006. doi:10.1002/art.30264.; Joly P, Bamberger N, Crickx B, et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol. 1994;130(5):663–665.; Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136(1):91–95. doi:10.1016/s0022-3476(00)90056-8.; Martini G, Ramanan AV, Falcini F, et al. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology. 2009;48(11):1410–1413. doi:10.1093/rheumatology/kep244.; Zulian F, Vallongo C, Woo P, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9): 2873–2881. doi:10.1002/art.21264.; Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–1988. doi:10.1080/21645515.2017.1316909.; Ihn H, Sato S, Fujimoto M, et al. Demonstrationмof interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995;287(2):193–197. doi:10.1007/BF01262331.; Nagaoka T, Sato S, Hasegawa M, et al. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. J Rheumatol. 2000;27(8):1917–1921.; Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the openlabel period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018;77(2):212–220. doi:10.1136/annrheumdis-2017-211682.; Foeldvari I, Anton Lopez J, Friswell M, et al. Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma. J Scleroderma Relat Disord. 2017;2(3):203–207. doi:10.5301/jsrd.5000259.; Martini G, Campus S, Raffeiner B, et al. Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases? Clin Exp Rheumatol. 2017;35 Suppl 106(4):211–213.; Lythgoe H, Baildam E, Beresford MW, et al. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Rheumatology (Oxford). 2018; 57(2):398–401. doi:10.1093/rheumatology/kex382.; Dubois EA, Cohen AF. Abatacept. Br J Clin Pharmacol. 2009; 68(4):480–481. doi:10.1111/j.1365-2125.2009.03502.x.; Bruni C, Praino E, Allanore Y, et al. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol. 2017;13(5):469–482. doi:10.1080/1744666X.2017.1263153.; Brunner HI, Tzaribachev N, Vega-Cornejo G, et al. Subcutaneous abatacept in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study. Arthritis Rheumatol. 2018;70(7):1144–1154. doi:10.1002/art.40466.; Khanna D, Spino C, Johnson S, et al. Abatacept in early diffuse cutaneous systemic sclerosis— results of a phase 2 investigatorinitiated, multicenter, double- blind randomized placebo-controlled trial. Arthritis Rheumatol. 2020;72(1):125–136. doi:10.1002/art.41055.; Fage SW, Arvesen KB, Olesen AB. Abatacept improves skin score and reduces lesions in patients with localized scleroderma: a case series. Acta Derm Venereol. 2018;98(4):465–466. doi:10.2340/00015555-2878.; Chimenti MS, Teoli M, Di Stefani A, et al. Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. Eur J Dermatol. 2013;23(2):273–274. doi:10.1684/ejd.2013.1929.; Ferguson ID, Weiser P, Torok KS. A case report of successful treatment of recalcitrant childhood localized scleroderma with infliximab and leflunomide. Open Rheumatol J. 2015;9:30–35. doi:10.2174/18743129014090100030.; Alcantara-Reifs CM, Garnacho-Saucedo GM, Salido-Vallejo R, et al. Imatinib treatment of therapy resistant generalized deep morphea. Dermatol Ther. 2015;28(5):271–273. doi:10.1111/dth.12248.; Schoch JJ, Schoch BS, Werthel JD, et al. Orthopedic complications of linear morphea: Implications for early interdisciplinary care. Pediatr Dermatol. 2017;35(1):43–46. doi:10.1111/pde.13336.; Torok KS. Pediatric scleroderma: systemic or localized forms. Pediatr Clin N Am. 2012;59:381–405. doi:10.1016/j.pcl.2012.03.011.; Mugii N, Matsushita T, Oohata S, et al. Long-term follow-up of finger passive range of motion in Japanese systemic sclerosis patients treated with self-administered stretching. Mod Rheumatol. 2019;29(3):484–490. doi:10.1080/14397595.2018.1466635.; Buckley SL, Skinner S, James P, Ashley RK. Focal scleroderma in children: an orthopaedic perspective. J Pediatr Orthop. 1993;13(6):784–790. doi:10.1097/01241398-199311000-00020.; Ghanem I, Karam JA, Widmann RF. Surgical epiphysiodesis indications and techniques: update. Curr Opin Pediatr. 2011;23(1): 53–59. doi:10.1097/MOP.0b013e32834231b3.; Daumas A, Magalon J, Delaunay F, et al. Fat Grafting for Treatment of Facial Scleroderma. Clin Plast Surg. 2020;47(1): 155–163. doi:10.1016/j.cps.2019.08.016.; Strong AL, Rubin JP, Kozlow JH, Cederna PS. Fat Grafting for the Treatment of Scleroderma. Plast Reconstr Surg. 2019;144(6): 1498–1507. doi:10.1097/PRS.0000000000006291.; Palmero ML, Uziel Y, Laxer RM, et al. En coup de sabre scleroderma and Parry-Romberg syndrome in adolescents: surgical options and patient-related outcomes. J Rheumatol. 2010;37(10): 2174–2179. doi:10.3899/jrheum.100062.; Wollina U, Buslau M, Heinig B, et al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extrem Wounds. 2007;6(4):291–298. doi:10.1177/1534734607308731.; Piram M, McCuaig CC, Saint-Cyr C, et al. Short- and long-term outcome of linear morphoea in children. Br J Dermatol. 2013; 169(6):1265–1271. doi:10.1111/bjd.12606.; Ardalan K, Zigler C, Torok K. Predictors of longitudinal quality of life in juvenile localized scleroderma. Arthritis Care Res. 2017; 69(7):1082–1087. doi:10.1002/acr.23101.
-
9Academic Journal
Συγγραφείς: A. V. Samtsov, Yu. N. Perlamutrov, M. M. Kokhan, E. V. Sokolovskiy
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 6, Pp 79-93 (2017)
Θεματικοί όροι: медицинская помощь, экзема, atopic dermatitis, treatment, псориаз, psoriasis, Dermatology, лечение, topic glucocorticosteroid agents, 3. Good health, дерматозы, 03 medical and health sciences, 0302 clinical medicine, топические глюкокортикостероиды, RL1-803, medical care, атопический дерматит, eczema, dermatoses
-
10Academic Journal
Συγγραφείς: M. G. Harchilava, E. A. Atayan, N. A. Benedik, V. R. Hayrutdinov, I. E. Belousova, A. V. Samtsov
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 4, Pp 49-53 (2017)
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, топические глюкокортикостероиды, вакцино-индуцированная псевдолимфома, акдс вакцина, RL1-803, the dpt vaccine, Dermatology, calcineurin inhibitors, ингибиторы кальциневрина, topical corticosteroids, vaccine-induced pseudolymphoma, 3. Good health
-
11Academic Journal
Συγγραφείς: M. G. Harchilava, E. A. Atayan, N. A. Benedik, V. R. Hayrutdinov, I. E. Belousova, A. V. Samtsov
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 4, Pp 49-53 (2017)
Θεματικοί όροι: вакцино-индуцированная псевдолимфома, топические глюкокортикостероиды, ингибиторы кальциневрина, акдс вакцина, vaccine-induced pseudolymphoma, topical corticosteroids, calcineurin inhibitors, the dpt vaccine, Dermatology, RL1-803
Περιγραφή αρχείου: electronic resource
Relation: https://www.vestnikdv.ru/jour/article/view/258; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294
Σύνδεσμος πρόσβασης: https://doaj.org/article/48ae322ca2c14d39b3c85431622f235d
-
12Academic Journal
Συγγραφείς: A. A. Kubanov, A. E. Karamova
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 1, Pp 104-110 (2017)
Θεματικοί όροι: аллергический контактный дерматит, этиология, лечение, топические глюкокортикостероиды, гидрокортизона 17-бутират, allergic contact dermatitis, etiology, treatment, topical glucocorticoids, hydrocortisone 17-butyrate, Dermatology, RL1-803
Περιγραφή αρχείου: electronic resource
Relation: https://www.vestnikdv.ru/jour/article/view/112; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294
Σύνδεσμος πρόσβασης: https://doaj.org/article/dc3380c6ac724f299148fd3a6d562c7a
-
13Academic Journal
Συγγραφείς: M. M. Kokhan, A. V. Samtsov, YU. N. Perlamutrov, E. V. Sokolovskiy
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 6, Pp 79-93 (2017)
Θεματικοί όροι: дерматозы, медицинская помощь, атопический дерматит, экзема, псориаз, лечение, топические глюкокортикостероиды, dermatoses, medical care, atopic dermatitis, eczema, psoriasis, treatment, topic glucocorticosteroid agents, Dermatology, RL1-803
Περιγραφή αρχείου: electronic resource
Relation: https://www.vestnikdv.ru/jour/article/view/289; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294
Σύνδεσμος πρόσβασης: https://doaj.org/article/57c3735099d04b3399008261654a2d80
-
14Academic Journal
Συγγραφείς: Alexey A. Kubanov, A. E. Karamova
Πηγή: Vestnik Dermatologii i Venerologii, Vol 0, Iss 1, Pp 104-110 (2017)
Θεματικοί όροι: 0301 basic medicine, аллергический контактный дерматит, treatment, etiology, Dermatology, лечение, 01 natural sciences, 3. Good health, 0104 chemical sciences, hydrocortisone 17-butyrate, 03 medical and health sciences, 0302 clinical medicine, топические глюкокортикостероиды, topical glucocorticoids, 13. Climate action, гидрокортизона 17-бутират, RL1-803, этиология, allergic contact dermatitis
-
15Academic Journal
Συγγραφείς: I. A. Larkova
Πηγή: Медицинский совет, Vol 0, Iss 14, Pp 77-80 (2015)
Θεματικοί όροι: атопический дерматит, дети, топические глюкокортикостероиды, atopic dermatitis, children, topical corticosteroids, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/364; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/6fcd0fde2fef4817b821ac459da2cb84
-
16Academic Journal
Περιγραφή αρχείου: text/html
-
17Academic Journal
Συγγραφείς: A.V. Emelianov, А.В. Емельянов
Πηγή: Current Pediatrics; Том 5, № 4 (2006); 87-91 ; Вопросы современной педиатрии; Том 5, № 4 (2006); 87-91 ; 1682-5535 ; 1682-5527
Θεματικοί όροι: топические глюкокортикостероиды, children, external therapy, pimecrolimus, topical corticosteroids, дети, наружная терапия, пимекролимус
Διαθεσιμότητα: https://vsp.spr-journal.ru/jour/article/view/762
-
18Academic Journal
Συγγραφείς: Кохан, Муза, Кениксфест, Юлия, Летаева, Ольга, Кащеева, Яна, Шайбакова, Юлия, Стукова, Евгения, Николаева, Кристина, Пахомова, Ирина
Θεματικοί όροι: АТОПИЧЕСКИЙ ДЕРМАТИТ, ЭКЗЕМА, ПУЗЫРЧАТКА, ТОПИЧЕСКИЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, ЭФФЕКТИВНОСТЬ, БЕЗОПАСНОСТЬ, КАЧЕСТВО ЖИЗНИ
Περιγραφή αρχείου: text/html
-
19Academic Journal
Συγγραφείς: M. V. Semenov, A. V. Zurochka, V. A. Zurochka, М. В. Семенов, А. В. Зурочка, В. А. Зурочка
Πηγή: Medical Immunology (Russia); Том 14, № 3 (2012); 233-238 ; Медицинская иммунология; Том 14, № 3 (2012); 233-238 ; 2313-741X ; 1563-0625 ; 10.15789/1563-0625-2012-3
Θεματικοί όροι: топические глюкокортикостероиды, flow cytometry, T-regulatory cells, topical glucocorticoids, проточная цитометрия, Т-регуляторные клетки
Περιγραφή αρχείου: application/pdf
Relation: https://www.mimmun.ru/mimmun/article/view/360/363; Козлов В.С. Роль и значение интраназальных кортикостероидов в лечении риносинуситов // Рос. Ринология. – 2003. – 3. – С. 20-24.; Ланцов А.А., Рязанцев С.В и соавт. Эпидемиология полипозных риносинуситов. – СПб.: РИА-АМИ, 1999. – 96 с.; Маянский, А.Н. Виксман М.К. Способ оценки функциональной активности нейтрофилов человека по реакции восстановления нитросинего тетразоля: метод. рек. – Казань, 1979. – 11 с.; Медицинские лабораторные технологии и диагностика: справочник / под ред. А.М. Карпищенко. – СПб.: Интермедика, 1999. – 656 с.; Новиков Д.К. Иммунология и аллерголоия для ЛОР-врачей. – М.: ООО ≪Медицинское информационное агенство≫, 2006. – 512 с.; Трофименко С.Л. Патогенез и клиника полипозного риносинусита // Вестн. Оториноларингологиии. – 2010. – 4. – С 94-97.; Ali M.S., Wilson J.A., Bennett M., Pearson J.P. Mucin gene expression in nasal polyps // Biol. Trace Elem. Res. – 2005; 106: 117 – Р. 139.; Bachert C., Geavert P. Effect of intranasal corticosteroids on release of cytokines and inflammatory mediators // Allergy. – 1999. – Vol. 54. – P. 116-123.; Brannan M.D., Seiberling M., Culter M.D., Cuss F.M., Affrime M.B. Lack of systemic activity with intranasal mometasone furoate. // J. Allergy Clin. Immunol. – 1996. – Vol. 97. – P. 198.; Chatila T.A. Role of regulatory T cells in human diseases // J. Allergy Clin. Immunol. – 2005; 116: 949-59.; Coste A. Brugel L., Maitre B., Boussat S., Papon J.F., Wingerstmann L., Peyn gre R., Escudier E. Inflammatory cells as well as epithelial cells in nasal polyps express vascular endothelial growth factor // Eur. Respir J. – 2000; 15: 367-72.; Davidsson A. Hellquist H.B. The so-called ‘allergic’ nasal polyp // Otorhinolaryngol Relat Spec. – 1993. – 55: 30-35.; Gosepath J., Brieger J., Gletsou E., Mann W.J. Expression and localization of cyclooxygenases (Cox-1 and Cox-2) in nasal respiratory mucosa. Does Cox-2 play a key role in the immunologyof nasal polyps? // J. Investig. Allergol. Clin. Immunol. – 2004. – 14 (2). – P. 114-8.; Liu W., Putnam A.L., Xu-Yu Z. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells // J. Exp. Med. – 2006. – Vol. 203, N 7. – P. 1701-1711.; Ponikau J.U., Sherris D.A., Kern E.B., Homburger H.A. The diagnosis and incidence of allergic fungal sinusitis // Mayo Clin. Proc. – 1999; 74: 877-884.; Sacaguchi S., Sacaguchi N., Asano M. Immunologic self-tolerance maintained by activated T-cells expressing IL-2 receptor a-chains (CD25) // J. Immunol. – 1995. – Vol. 155. – P. 1151-1164.; Sasaci Y., Sakai M., Miyazaki S., Higuma S., Shiozaki A., Saito S. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases // Mol. Hum. Reprod. – 2004 – P. 347-353.; Schenkel E.J., Skonner D.R., Bronsky E.A., David Miller S., Pearlman David S., Rooklin A., Rosen J.P., Ruff M.E.,Vandewalker M.L., Wanderer A., Damaraju C.V., Nolop K.B., and Mesarina-Wicki B. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueos nasal spray // Pediatrics. – 2000. – Vol. 105. – P. 22.; Schubert L.A., Jeffery E., Zhang Y., Ramsdell F., Ziegler S.F. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation // J. Biol. Chem. – 2001; 276: 37672-37679.; Settipane G.A., Chafee F.H. Nasal polyps in asthma and rhinitis // J. Allergy Clin. Immunol. – 1977; 59: 17-21.; Shi H.Z., Li S., Xie X. F. Qin X.J., Qin X., Zhong X.N. Regulatory CD4+CD25+ T lymphocytes in peripheral blood from patients with atopic asthma // Clin. Immunol. – 2004. – Vol. 113. – P. 172-178.; https://www.mimmun.ru/mimmun/article/view/360
-
20Academic Journal
Συγγραφείς: Батыршина, С.
Θεματικοί όροι: ТОПИЧЕСКИЕ ГЛЮКОКОРТИКОСТЕРОИДЫ, МЕХАНИЗМ ДЕЙСТВИЯ, КЛАССИФИКАЦИЯ, ФАРМАКОЛОГИЧЕСКИЙ ОТВЕТ, ВАРИАНТЫ НАЗНАЧЕНИЯ У ДЕТЕЙ
Περιγραφή αρχείου: text/html
